Table 1. Baseline data stratified by fibrosis stage for the development of e antigen chronic hepatitis B fibrosis (EPLF) score.
| F0 (n=32) | F1 (n=80) | F2 (n=47) | F3 (n=20) | F4 (n=33) | |
|---|---|---|---|---|---|
| Age(years) | 30.9±8.8 | 32.2±9.2 | 33.73±10.43 | 38.6±9.97 | 38.36±10.36 |
| Gender(male,%) | 21(65.5) | 54(67.5) | 26(55.3) | 15(75) | 28(84.8) |
| Albumin(g/dL) | 44.32±3.11 | 44.25±3.62 | 43.29±3.67 | 40.6±3.39 | 41.05±5.08 |
| ALT(IU/L) | 34(14-332) | 54(10-639) | 47(13-2302) | 65(10-712) | 49(23-1423) |
| AST(IU/L) | 25(16-128) | 38(16-130) | 40(16-1458) | 50(17-353) | 46(21-1849) |
| TB(umol/dL) | 13.1(7.7-52.4) | 13.2(4.7-167) | 14.9(6.1-96.1) | 13.4(2.1-100) | 16.9(8.7-120) |
| GGT(IU/L) | 20.5(7-73) | 21(10-295) | 22(10-366) | 50(17-353) | 45(16-245) |
| AKP(IU/L) | 73(22-140) | 77(38-154) | 81(11-207) | 93(40-158) | 88(32-214) |
| WBC(×109/L) | 4.67±1.32 | 6.75±1.33 | 4.99±1.29 | 5.41±1.47 | 4.59±1.59 |
| HB(g/L) | 150±19 | 150±17.8 | 144.7±14 | 147.8±22.4 | 144.3±21.8 |
| Platelet count | 206±65 | 200.6±61.3 | 185.5±51.2 | 161.8±43.5 | 150±42.8 |
| (×109/L) | |||||
| HBV DNA | 7.8±1.0 | 7.7±1.0 | 7.3±1.4 | 6.7±1.3 | 6.4±1.2 |
| (Log10copies/mL) | |||||
| HBeAg(PEIU/mL) | 264.2 (1.54-384.3) | 233.2 (1.79-404.5) | 118.9 (1.27-291.7) | 5.60 (1.29-226.1) | 2.71 (1.21-216.9) |
| HBsAg(IU/mL) | 54619 (4.31-66222.2) | 35561.8 (136-72495 | 17048 (80.2-31622.7) | 5662.2 (342-13629.1) | 2469.6 (21.2-34027) |
| BMI | 23±1.7 | 22±1.8 | 21.9±2.2 | 22.2±2.8 | 23.2±1.2 |
BMI, body mass index; AKP, alkaline phosphatase; GGT, γ-glutamyltransferase; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen ; HBeAg, hepatitis B e antigen; WBC, white blood cell count; PLT, Platelet.
Continuous variables are presented as mean and standard deviation ; categorical variables are expressed as counts and medians.